Univariable associations between HLA-B27 and positive family history stratified by geographical region
HLA-B27+ n=1609 | HLA-B27− n=439 | OR (95% CI) | P value | |
Positive family history of axSpA | ||||
Total population | ||||
Present | 518 | 90 | 1.84 (1.43 to 2.38) | <0.001 |
Absent | 1087 | 348 | Ref | |
Per geographical region | ||||
Asia | 144/487 | 11/58 | 4.19 (2.24 to 7.83) | <0.001 |
Europe and North America | 196/658 | 30/182 | 2.09 (1.40 to 3.13) | <0.001 |
Latin America | 37/164 | 3/38 | 3.95 (1.21 to 12.89) | 0.023 |
Middle East and North Africa | 141/300 | 46/161 | 0.98 (0.69 to 1.40) | 0.917 |
Positive family history of uveitis | ||||
Total population | ||||
Present | 66 | 10 | 1.81 (0.92 to 3.56) | 0.084 |
Absent | 1537 | 422 | Ref | |
Per geographical region | ||||
Asia | 12/487 | 0/58 | n.a. | n.a. |
Europe and North America | 28/658 | 5/182 | 1.54 (0.59 to 4.01) | 0.379 |
Latin America | 6/164 | 1/38 | 1.65 (0.20 to 13.72) | 0.644 |
Middle East and North Africa | 20/300 | 4/161 | 1.37 (0.47 to 4.04) | 0.565 |
Positive family history of ReA | ||||
Total population | ||||
Present | 14 | 3 | 1.26 (0.36 to 4.40) | 0.719 |
Absent | 1583 | 427 | Ref | |
Per geographical region | ||||
Asia | 5/487 | 0/58 | n.a. | n.a. |
Europe and North America | 5/658 | 1/182 | 1.35 (0.16 to 11.58) | 0.785 |
Latin America | 2/164 | 0/38 | n.a. | n.a. |
Middle East and North Africa | 2/300 | 2/161 | 0.27 (0.04 to 1.92) | 0.191 |
Positive family history of IBD | ||||
Total population | ||||
Present | 47 | 27 | 0.45 (0.28 to 0.74) | 0.001 |
Absent | 1551 | 403 | Ref | |
Per geographical region | ||||
Asia | 0/487 | 1/58 | n.a. | n.a. |
Europe and North America | 34/658 | 17/182 | 0.52 (0.29 to 0.94) | 0.030 |
Latin America | 0/164 | 3/38 | n.a. | n.a. |
Middle East and North Africa | 13/300 | 6/161 | 0.56 (0.21 to 1.49) | 0.247 |
Positive family history of psoriasis | ||||
Total population | ||||
Present | 148 | 57 | 0.68 (0.49 to 0.94) | 0.020 |
Absent | 1461 | 382 | Ref | |
Per geographical region | ||||
Asia | 9/487 | 0/58 | n.a. | n.a. |
Europe and North America | 98/658 | 34/182 | 0.75 (0.50 to 1.13) | 0.172 |
Latin America | 13/164 | 4/38 | 0.85 (0.28 to 2.62) | 0.777 |
Middle East and North Africa | 28/300 | 19/161 | 0.39 (0.21 to 0.70) | 0.002 |
axSpA, axial spondyloarthritis; HLA-B27, human leucocyte antigen B27; IBD, inflammatory bowel disease; n.a., not available; ReA, reactive arthritis; Ref, reference category.